Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Anaplastic ependymoma is a rare, malignant type of ependymoma that most often arises in the supratentorial region of the brain of children and young adults and that manifests with variable symptoms including headaches, nausea, vision impairment, memory loss and difficulty walking.
Biomarker and diagnostic research for anaplastic ependymoma has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE3, 3 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03750513](https://clinicaltrials.gov/study/NCT03750513) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 8:51 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma |
PHASE1 |
M.D. Anderson Cancer Center |
RECRUITING |
[NCT04978727](https://clinicaltrials.gov/study/NCT04978727) | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | PHASE1 | Children's Oncology Group | ACTIVE_NOT_RECRUITING |
[NCT05057702](https://clinicaltrials.gov/study/NCT05057702) | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma | NA | University of California, San Francisco | RECRUITING |
[NCT05278208](https://clinicaltrials.gov/study/NCT05278208) | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | PHASE1 | Nationwide Children's Hospital | RECRUITING |
[NCT01096368](https://clinicaltrials.gov/study/NCT01096368) | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | PHASE3 | Children's Oncology Group | UNKNOWN |
124 publications have been identified in PubMed for anaplastic ependymoma. Research spans Review / Meta-Analysis (25%), Basic Science / Preclinical (25%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 31 | 25% |
Laboratory research | 31 | 25% |
Patient case studies | 25 | 20% |
Testing and diagnosis research | 13 | 10% |
Clinical study results | 10 | 8% |
Disease patterns and progression | 8 | 6% |
New treatment approaches | 4 | 3% |
Other research | 2 | 2% |
Martell E (2026). [PMID: 41825848](https://pubmed.ncbi.nlm.nih.gov/41825848/). *Cancer Lett*. [Review / Meta-Analysis]
Zhang J (2026). [PMID: 41882358](https://pubmed.ncbi.nlm.nih.gov/41882358/). *Nature*. [Basic Science / Preclinical]
Gobel E (2026). [PMID: 42011997](https://pubmed.ncbi.nlm.nih.gov/42011997/). *Biomol Biomed*. [Basic Science / Preclinical]
Bulut Ç (2026). [PMID: 41846303](https://pubmed.ncbi.nlm.nih.gov/41846303/). *Pediatr Blood Cancer*. [Other]
Munakomi S (2026). [PMID: 29083628](https://pubmed.ncbi.nlm.nih.gov/29083628/). *Unknown Journal*. [Basic Science / Preclinical]
Wang L (2026). [PMID: 41285250](https://pubmed.ncbi.nlm.nih.gov/41285250/). *Mod Pathol*. [Clinical Trial Publication]
Cooper E (2026). [PMID: 41634415](https://pubmed.ncbi.nlm.nih.gov/41634415/). *Nat Genet*. [Basic Science / Preclinical]
Arora S (2026). [PMID: 41159380](https://pubmed.ncbi.nlm.nih.gov/41159380/). *Neuro Oncol*. [Basic Science / Preclinical]
Karsonovich T (2026). [PMID: 30571036](https://pubmed.ncbi.nlm.nih.gov/30571036/). *Unknown Journal*. [Clinical Trial Publication]
Jeong D (2026). [PMID: 41813893](https://pubmed.ncbi.nlm.nih.gov/41813893/). *Nature*. [Basic Science / Preclinical]